Dermatology
Targeting GPP: A Guide for Dermatologists on Diagnosis, Burden, Management and Therapeutic Breakthroughs
DURATION
45 min
PROFESSION
Specialist
# OF CREDITS
0.75
ACCREDITATION
MOC - Section 3
EXPIRY DATE
2026-04-07
This is a 45-minute MOC Section 3 accredited eCME program for Canadian HCPs. This program is designed to provide practical, evidence-based insights into the diagnosis and management of generalized pustular psoriasis (GPP), a rare, chronic skin condition with potentially life-threatening flares. Using a patient case study, this program will examine the clinical presentation and chronic nature of GPP, including its lifelong physical, emotional, and psychosocial impacts. The role of the interleukin-36 (IL-36) receptor pathway in disease pathogenesis, and strategies for managing and preventing GPP flares will also be explored. Particular emphasis will be placed on spesolimab, a recently Health Canada-approved, first-in-class IL-36 receptor antagonist designed specifically for GPP treatment.
This program has received financial support from Boehringer Ingelheim in the form of an unrestricted educational grant.
Faculty
- Jessica Chan, MD, CCFP
- Marni Wiseman, MD, FRCPC, DABD
- Natalie Skinner, MD, CCFP (EM), DipDerm
- Rachel Asiniwasis, MD, FRCPC
Learning objectives
Upon completion of this continuing education program participants will be better able to:
- Recognize the clinical presentation, burden and chronicity of generalized pustular psoriasis (GPP)
- Implement evidence-based therapy for GPP management and flare prevention in clinical practice
- Counsel patients about GPP management and flare prevention
Accreditation
This activity is an Accredited Self-Assessment Program (Section 3) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada. You may claim a maximum of 0.75 hours (credits are automatically calculated).
#
of credits: 0.75
Duration: 45 min
FAQs & HELP
MDBriefCase Group specializes in accredited, online continuing professional development (CPD) programs, custom tailored for specific international markets and available on a convenient online platform.
All content is developed by leading specialists and peer-reviewed by experts at respected institutions, which keeps more than 280,000 global healthcare professionals at the forefront of the latest evidence and protocols worldwide.
The vast majority of our programs are accredited by one or more respected institutions. We do provide unaccredited content to ensure that healthcare professionals have access to relevant practical resources in addition to accredited learning.
Specific accrediting information (including the accrediting body, along with the type and number of credits) can be found on the “Main” page and/or “Accreditation” page of each program. In order to qualify for accreditation and obtain your certificate, you must successfully complete the requirements listed on the “Accreditation” or “CME Information” pages available in each program.
MDBriefCase Group works with various institutions to provide peer-reviewed, up-to-date accredited content. Our programs and resources are provided via collaboration between medical writers, faculty members, associations, universities and other relevant organizations. The content you were recommended is likely valued by your society or association and is conveniently provided to you free of charge on an MDBriefCase Group platform.
Specific accrediting information (including the accrediting body, along with the type and number of credits) can be found on the “Main” page and/or “Accreditation” page of each program. In order to qualify for accreditation and obtain your certificate, you must successfully complete the requirements listed on the “Accreditation” or “CME Information” pages available in each program.
If you are interested in learning more about supporting one of our programs, please contact us.
If you are interested in working with MDBriefCase Group as a writer or committee member, please contact us.
To access the MDBriefCase Group privacy policy, please click here.
No, registration with MDBriefCase is free!
To access your profile, visit My Profile. If you would like to update the information here don’t forget to hit the ‘save’ button when you are finished. Your profile is where you can control what email communications you receive.
If you have forgotten your password, you can reset your password. To access this page from the Login page, click Forgot password. Enter the email address you registered with and you will receive an email with a link to reset your password.
Please note: if you submitted multiple password resets, only the link on the most recent email is valid.
You can unsubscribe from MDBriefCase Group emails by clicking the unsubscribe button located at the bottom of each of our emails.
45 min
Duration
Specialist
Profession
0.75
# of credits
Learning Objectives
Upon completion of this continuing education program participants will be better able to:
- Recognize the clinical presentation, burden and chronicity of generalized pustular psoriasis (GPP)
- Implement evidence-based therapy for GPP management and flare prevention in clinical practice
- Counsel patients about GPP management and flare prevention
MOC - Section 3
ACCREDITATION
Dermatology
Learning Category
Psoriasis
Topic
0
Price
2026-04-07
Expiry Date
CAN-eng
Region/Language
Course Description
This is a 45-minute MOC Section 3 accredited eCME program for Canadian HCPs. This program is designed to provide practical, evidence-based insights into the diagnosis and management of generalized pustular psoriasis (GPP), a rare, chronic skin condition with potentially life-threatening flares. Using a patient case study, this program will examine the clinical presentation and chronic nature of GPP, including its lifelong physical, emotional, and psychosocial impacts. The role of the interleukin-36 (IL-36) receptor pathway in disease pathogenesis, and strategies for managing and preventing GPP flares will also be explored. Particular emphasis will be placed on spesolimab, a recently Health Canada-approved, first-in-class IL-36 receptor antagonist designed specifically for GPP treatment.
This program has received financial support from Boehringer Ingelheim in the form of an unrestricted educational grant.
Faculty
- Jessica Chan, MD, CCFP
- Marni Wiseman, MD, FRCPC, DABD
- Natalie Skinner, MD, CCFP (EM), DipDerm
- Rachel Asiniwasis, MD, FRCPC
Accreditation
This activity is an Accredited Self-Assessment Program (Section 3) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada. You may claim a maximum of 0.75 hours (credits are automatically calculated).
45 min
Duration
0
Price
0.75
# of credits
